These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11181692)

  • 1. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
    Vikram B
    J Clin Oncol; 2001 Feb; 19(4):1233-4. PubMed ID: 11181692
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
    Brizel DM; Wasserman TH; Henke M; Strnad V; Rudat V; Monnier A; Eschwege F; Zhang J; Russell L; Oster W; Sauer R
    J Clin Oncol; 2000 Oct; 18(19):3339-45. PubMed ID: 11013273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amifostine reduces radiation therapy-induced dry mouth in head and neck cancer patients.
    Oncology (Williston Park); 2004 Sep; 18(10):1314, 1316. PubMed ID: 15526835
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer.
    Anné PR
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):80-3. PubMed ID: 12577250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized double-blind trial of amifostine versus placebo for radiation-induced xerostomia in patients with head and neck cancer.
    Lee MG; Freeman AR; Roos DE; Milner AD; Borg MF
    J Med Imaging Radiat Oncol; 2019 Feb; 63(1):142-150. PubMed ID: 30461207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial.
    Wasserman TH; Brizel DM; Henke M; Monnier A; Eschwege F; Sauer R; Strnad V
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):985-90. PubMed ID: 16253773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Has the outlook improved for amifostine as a clinical radioprotector.
    Wasserman TH; Brizel DM
    Radiother Oncol; 2001 Sep; 60(3):334-6. PubMed ID: 11570362
    [No Abstract]   [Full Text] [Related]  

  • 8. Radioprotection of head and neck tissue by amifostine.
    Strnad V; Sauer R
    Front Radiat Ther Oncol; 2002; 37():101-11. PubMed ID: 11764651
    [No Abstract]   [Full Text] [Related]  

  • 9. Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection?
    Vacha P; Fehlauer F; Mahlmann B; Marx M; Hinke A; Sommer K; Richter E; Feyerabend T
    Strahlenther Onkol; 2003 Jun; 179(6):385-9. PubMed ID: 12789464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of amifostine to prevent xerostomia in patients receiving radiation therapy.
    Batcha M
    Oncol Nurs Forum; 2000 May; 27(4):615-6. PubMed ID: 10833684
    [No Abstract]   [Full Text] [Related]  

  • 11. Amifostine: a radioprotector in locally advanced head and neck tumors.
    Wagner W; Prott FJ; Schonekas KG
    Oncol Rep; 1998; 5(5):1255-7. PubMed ID: 9683846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comments on five clinical trials concerning radiotherapy-induced mucositis in patients with head and neck neoplasms].
    Noël G; Mazeron JJ
    Cancer Radiother; 2001 Apr; 5(2):202-4. PubMed ID: 11355589
    [No Abstract]   [Full Text] [Related]  

  • 13. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
    Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of amifostine on late radiation-toxicity in head and neck cancer--a follow-up study.
    Büntzel J; Glatzel M; Mücke R; Micke O; Bruns F
    Anticancer Res; 2007; 27(4A):1953-6. PubMed ID: 17649803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical use of radioprotector amifostine (YM-08310)].
    Takahashi I; Mitsuhashi N; Itoh J; Okazaki A; Ikeda H; Suto H; Yamakawa M; Nozaki M; Miyaishi K; Niibe H
    Nihon Igaku Hoshasen Gakkai Zasshi; 1984 Nov; 44(11):1396-404. PubMed ID: 6099539
    [No Abstract]   [Full Text] [Related]  

  • 16. Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma.
    Bourhis J; Rosine D
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):61-2. PubMed ID: 12577247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation.
    Braaksma M; Levendag P
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):63-70. PubMed ID: 12577248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective effect of amifostine on dental health after radiotherapy of the head and neck.
    Rudat V; Meyer J; Momm F; Bendel M; Henke M; Strnad V; Grötz K; Schulte A
    Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1339-43. PubMed ID: 11121631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy.
    Bardet E; Martin L; Calais G; Tuchais C; Bourhis J; Rhein B; Feham N; Alphonsi M
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):57-60. PubMed ID: 12577246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current status of prevention and management of radiation-induced xerostomia].
    Ma DY; Qiu WL; Zhang CP
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2010 Feb; 45(2):121-3. PubMed ID: 20368009
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.